Clinical evaluation of an anatomy-based patient specific quality assurance system by Hauri, P et al.
a Corresponding author: Stephanie Lang, Department of Radiation Oncology, University Hospital Zurich, Rämistr. 
100, 8091 Zürich, Switzerland; phone: 0041 44 255 4238; fax: 0041 44 2554547; email: stephanie.lang@usz.ch
Clinical evaluation of an anatomy-based patient specific 
quality assurance system
Pascal Hauri, Sarah Verlaan, Shaun Graydon, Linda Ahnen,  
Stephan Klöck and Stephanie Langa
Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
stephanie.lang@usz.ch
Received 26 July, 2013; accepted 27 November, 2013
The Delta4DVH Anatomy 3D quality assurance (QA) system (ScandiDos), which 
converts the measured detector dose into the dose distribution in the patient geom-
etry was evaluated. It allows a direct comparison of the calculated 3D dose with the 
measured back-projected dose. In total, 16 static and 16 volumetric-modulated arc 
therapy (VMAT) fields were planned using four different energies. Isocenter dose 
was measured with a pinpoint chamber in homogeneous phantoms to investigate 
the dose prediction by the Delta4DVH Anatomy algorithm for static fields. Dose dis-
tributions of VMAT fields were measured using GAFCHROMIC film. Gravitational 
gantry errors up to 10° were introduced into all VMAT plans to study the potential 
of detecting errors. Additionally, 20 clinical treatment plans were verified. For static 
fields, the Delta4DVH Anatomy predicted the isocenter dose accurately, with a devia-
tion to the measured phantom dose of 1.1% ± 0.6%. For VMAT fields the predicted 
Delta4DVH Anatomy dose in the isocenter plane corresponded to the measured dose 
in the phantom, with an average gamma agreement index (GAI) (3 mm/3%) of 
96.9 ± 0.4%. The Delta4DVH Anatomy detected the induced systematic gantry error 
of 10° with a relative GAI (3 mm/3%) change of 5.8% ± 1.6%. The conventional 
Delta4PT QA system detected a GAI change of 4.2% ± 2.0%. The conventional 
Delta4PT GAI (3 mm/3%) was 99.8% ± 0.4% for the clinical treatment plans. The 
mean body and PTV-GAI (3 mm/5%) for the Delta4DVH Anatomy were 96.4% ± 
2.0% and 97.7% ± 1.8%; however, this dropped to 90.8% ± 3.4% and 87.1% ± 4.1% 
for passing criteria of  3 mm/3%. The anatomy-based patient specific quality assur-
ance system predicts the dose distribution correctly for a homogeneous case. The 
limiting factor for the error detection is the large variability in the error-free plans. 
The dose calculation algorithm is inferior to that used in the TPS (Eclipse).
PACS numbers: 87.56.Fc, 87.56.-v
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I. IntroductIon
Patient-specific quality assurance (QA) for intensity-modulated techniques is often performed 
by comparing measured with calculated dose distributions in a QA phantom. The patient plan 
is calculated on the QA phantom in the treatment planning system (TPS) and then irradiated. A 
gamma agreement index (GAI, percentage of point passing the criteria)(1) for the plan is calcu-
lated using different acceptance criteria for the dose difference (DD) and distance to agreement 
(DTA).(1) This method, using the conventional Delta4PT (ScandiDos, Uppsala, Sweden) device, 
has been proven to be accurate and reproducible.(2-4)
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However, there is a lack of correlation between conventional QA and dose errors in the 
patient anatomy.(5) The points, which do not pass the acceptance criteria, can be viewed in the 
Delta4PT detector array, but nothing can be concluded on the clinical relevance of these points. 
A solution might be a patient anatomy-based QA system. The principle of such a system is to 
measure the dose of the patient plan as for conventional QA in a phantom, and then remap the 
measured dose distribution to the CT dataset of the patient. This allows a direct comparison of 
the planned and the measured back-projected, three-dimensional (3D) dose to the patient. An 
advantage compared to conventional QA is that the GAI can be individually evaluated based 
on the patient body, the planning target volume (PTV), and organs at risk (OAR). Clinically 
relevant dose comparisons can be achieved. Additionally, organ specific dose-volume histo-
grams (DVH) can be compared with the TPS predicted DVHs (Fig. 1). This allows discussion 
regarding potentially necessary clinical plan adjustments with the clinicians, in case of poor 
agreement in the patient’s DVH Anatomy analysis. Additionally, patient anatomy-based QA 
systems could replace independent monitor units (MU) checks in the patient geometry.
Only a limited number of measurement-based 3D anatomy dose QA devices are clinically 
available: The 3DVH (Sun Nuclear Corporation, Melbourne, FL), the MatriXXEvolution (IBA 
Dosimetry, Schwarzenbruck, Germany) , Delta4DVH Anatomy (ScandiDos, Uppsala, Sweden). 
The measurement for Delta4DVH Anatomy and the 3DVH system is performed in a stationary 
phantom, while the measurement device for the MatriXXEvolution is mounted on the gantry 
head and rotates together with the gantry.(6) The Delta4DVH Anatomy and the MatriXXEvolution 
use independent dose calculation algorithms, which calculate the dose to the patient using the 
energy fluency. The 3DVH does not recalculate the dose; instead it perturbs the TPS patient 
planned dose to account for known errors measured in the conventional QA.(7,8) 
This paper describes the evaluation of a new commercially available anatomy-based QA 
system. The isocenter dose in a homogeneous phantom was measured to investigate the accuracy 
of the algorithm for static fields. The dose distribution was measured in the isocenter plane of 
two different homogeneous phantoms to compare the measured dose with the dose calculated 
by patient anatomy-based QA algorithm for VMAT fields. To investigate the error detection 
capability of the system, an error-induced treatment plan was created. Furthermore, a patient 
study was performed with ten plans for prostate cancer and ten plans for intracranial lesions.
 
II. MAtErIALS And MEtHodS
Four different experiments are described more in detail in the following sections. First, the 
Delta4 Anatomy Option was evaluated for static fields in a homogeneous phantom. Second, it 
was tested for volumetric-modulated arc therapy (VMAT) fields in a homogeneous phantom. 
Third, for 20 patient plans (prostate cancer and intracranial lesions), conventional gamma 
analysis was compared with the analysis using the Delta4 Anatomy Option. Finally, we evalu-
ated the capability of the system to detect gantry positional errors.
Fig. 1. DVHs of the PTV and OAR for a prostate cancer patient. The thin lines are the TPS calculated and the large round 
points are the measured reprojected Delta4DVH Anatomy DVHs.
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A.  treatment planning 
Treatment planning was performed in Eclipse (Varian Medical Systems, Palo Alto, CA) treatment 
planning system (TPS). Dose calculation was done using the anisotropic analytical algorithm 
(AAA 8.9)(9) with a calculation grid size of 2.5 mm. Sixteen open static fields were planned 
for the homogeneous OCTAVIUS (PTW, Freiburg, Germany) phantom with field sizes of 2 × 
2 cm2, 5 × 5 cm2, 10 × 10 cm2, and 20 × 20 cm2 using four different energies (6 MV (X6), 
10 MV (X10), X6 flattening filter free (X6FFF), and X10 flattening filter-free (X10FFF)). 
Additionally, 16 VMAT fields were planned on two homogenous phantoms (OCTAVIUS and 
solid slab water-equivalent phantom), simulating prostate treatments. For each phantom, one 
plan with two fields per energy was created. The progressive resolution optimizer (PRO 8.9) 
was used. A dose of 2 Gy per fraction was prescribed to the prostate PTV. Four OARs were 
contoured (rectum, bladder, and bilateral heads of femur) on the two phantoms and considered 
during optimization. Additionally, for ten nonconsecutive prostate cancer patients and ten 
patients with large intracranial lesions, treatment plans were performed prescribing 2–5 Gy 
per fraction to the PTV. All prostate patients were planned with a rectal balloon to protect the 
posterior part of the rectum.
A.1 Introduced gantry positional error
A gantry positional error was introduced into the treatment plan to test the ability of the system 
to evaluate treatment delivery errors. An in-house developed software program (in MATLAB, 
The MathWorks, Natick, MA) manipulates the treatment plan header of the exported DICOM 
plan file by overwriting the angle at each control point with the error-introduced gantry angle. 
The gravitational response of the error is simulated with a sinusoid function to maximize the 
displacement when the gantry is perpendicular to the gravitational force (gantry at 90° and 
270°) and to have a zero displacement at 0° and 180°.
B.  treatment delivery and dose measurements
B.1 Linear accelerator
All measurements were performed at the University Hospital Zurich (USZ) using the TrueBeam 
(Varian Medical Systems) linear accelerator. The energy modes X6, X10, X6FFF and X10FFF 
were used. The linear accelerator is calibrated such that 100 MU corresponds to 1 Gy at a depth 
of maximum dose for a field size of 10 × 10 cm2 at a source surface distance (SSD) of 100 cm. 
The linear accelerator is equipped with a high-definition multileaf collimator system (HDMLC). 
The HDMLC has 60 leaf pairs with a total length of 22 cm. The inner 8 cm are covered by 32 
leaf pairs with a width of 0.25 cm. The outer 28 leaf pairs have a width of 0.5 cm. The dosim-
etric properties are described in more detail by Hrbacek et al.(10)
B.2 Delta4PT phantom measurements
Dose measurements were performed using the Delta4PT (ScandiDos) phantom. Delta4PT is a 
cylindrical phantom for pretreatment patient QA. Absolute dose is measured in 1069 p-Si diode 
detectors arranged in two orthogonal detector arrays. The space between the detectors is 5 mm 
in the central section of the array (8 × 8 cm2) and 10 mm outside (20 × 20 cm2). The diameter 
of the detectors is 1 mm. Properties of the phantom have been described in detail by Bedford 
et al.(11) and Sadagopan et al.(2)
B.3  Ion chamber measurements for static fields 
The OCTAVIUS phantom has an orthogonal shape. It is 32 cm wide and has a length of 32 cm. 
Three water-equivalent solid slabs of 31 × 10 × 2.2 cm3 are inserted in the 30 × 30 × 2.2 cm3 
central cavity to allow the measurement with GAFCHROMIC film (GF) or PinPoint (PTW-
Freiburg) chamber (PC). The phantom is described in detail by Van Esch et al.(12)
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Isocenter dose in the OCTAVIUS phantom was measured using the PC. The chamber model 
31016 with an inner diameter of 2.9 mm shows a flat angular response, as the measuring volume 
is approximately spherical. 
B.4  GAFCHROMIC film measurements for VMAT fields
The dose distributions in the frontal isocenter plane were measured in the two phantom patients 
using GF EBT2 (ISP, Wayne, NJ and Ashland Inc., Covington KY). For each sheet of film, an 
individual five step calibration was performed by irradiating five 5 × 3.2 cm2 pieces of film, 
from 0 up to 300 MU in 75 MU steps with the X6 beam. 
The films were scanned with a resolution of 150 dpi, resulting in a distance between two 
measurement points of 0.17 mm. The red channel transmission values were used for dose 
conversion and the blue channel values for film thickness correction.
The GF was placed on the top of the solid slabs inserted in the OCTAVIUS phantom and 
the VMAT plans were irradiated.
The water-equivalent RW3 slab phantom (PTW) was constructed with 20 10 mm slabs with 
a diameter of 30 × 30 cm2.(13) The GF was placed in the central horizontal plane of the 20 × 
30 × 30 cm3 water phantom, where the dose distributions of the VMAT plans were measured. 
In a prestudy, we’ve evaluated the accuracy of the film dosimetry set up in our department and 
found a dose uncertainty of 1.8%.
c.  Anatomy dose calculation algorithm
The Anatomy dose (3D dose to patient) algorithm calculates the delivered dose to the patient’s 
anatomy, based on the patient’s CT. For each control point in a VMAT beam, the patient dose 
calculation algorithm converts the in the Delta4PT measured detector doses in two steps.(14) 
First, out of the measured dose in the detector array, the energy fluence is approximated using 
a pencil beam algorithm. Then the energy fluence is applied to the inhomogeneous patient 
geometry and the dose is calculated using the same pencil beam algorithm.
The pencil beam algorithm in the Delta4DVH Anatomy option is commissioned using the 
three-dimensional dose distributions of open squared fields (3 × 3 cm2 to 40 × 40 cm2), exported 
from the treatment planning system. Additionally, headscatter factors for the same field sizes 
are needed.
The Delta4DVH Anatomy option allows the comparison of the back-projected measured patient 
anatomy dose with the TPS planned patient dose. Dose distributions can be compared based on 
DVHs or GAI. This GAI is calculated separately for each OAR, PTV, and body structure. The 
calculation grid size of the anatomy dose calculation algorithm is the same as in the TPS.
d.  Analysis of the measurements
D.1  Static field evaluation
The isocenter dose in the TPS and the Anatomy option in the two phantoms were determined 
and additionally the dose was measured. Relative dose differences were calculated. Mean and 
standard deviation were determined over the four measured open fields of 2 × 2 cm2, 5 × 5 cm2, 
10 × 10 cm2, and 20 × 20 cm2 for each energy (X6, X10, X6FFF, X10FFF).
D.2  VMAT phantom plan evaluation
The dose distributions obtained during the measurements described above were compared 
(Fig. 2). Four different comparisons were made, all resulting in a GAI: 
1. The calculated dose distribution exported from the TPS was compared to the back-projected 
dose distribution calculated by the Delta4 Anatomy software in three dimensions  (Anatomy 
GAI)
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2.  The calculated dose distribution in the isocenter plane exported from the TPS was compared 
to the GF measurement (TPS-Phantom GAI)
3.  The back-projected dose distribution in the isocenter plane calculated by the Delat4 Anatomy 
software was compared to the measured GF dose distribution (Anatomy-Phantom GAI),
4. The Delta4 measurement was compared to the dose calculated on the Delta4 phantom 
(Conventional GAI).
 
 
Measurement 
using Gafchromic 
film in the patient 
surrogate 
Measurement 
with Delta4 
phantom  
Calculation on 
Delta4 
phantom  
Backprojected ‚measured’ 
dose in the patient 
surrogate  
Calculated dose in the patient surrogate  
Fig. 2. Evaluation of the Anatomy option using two phantoms as patient surrogates. A plan is calculated on a phantom 
and a verification plan is done on the Delta4 phantom. The plan is irradiated on the Delta4 phantom and on the patient 
surrogate phantom with a GAFCHROMIC film inserted. From the Delta4 measurements, the dose is back-projected to the 
patient anatomy. The different calculated and measured dose distributions are compared (indicated with yellow arrows 
in the figure).
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D.3  VMAT patient plan evaluation
Ten treatment plans for prostate cancer treatment and ten plans for intracranial lesions with 2–3 
VMAT fields were investigated. The planned dose distributions for the patients were exported 
from the TPS to the ScandiDos QA software. The plans were measured on the Delta4PT phan-
tom and the dose was back-projected onto the patient in the Delta4DVH Anatomy software. The 
conventional GAI and a PTV and body structure GAI were calculated.
D.4 Gamma analysis and statistics
For the phantom study, the dose planes were evaluated using a GAI.(1) As gamma criteria, 1 up 
to 3 mm DTA combined with 1% up to 3% DD (from isocenter dose, which was for all plans in 
the high-dose region) were used. For the VMAT patient plan evaluation, a DD of 3% and 5% 
and a DTA of 3 mm were used. Voxels with less than 20% of the isocenter dose were not taken 
into account. This ensured that the analysis was focused on the clinically relevant region. The 
calculated dose was used as reference.
The two VMAT fields per plan were measured separately and evaluated together. Mean and 
standard deviation (SD) of dose difference, GAI, and GAI-change were calculated. All values 
in the result part are given as mean ± SD.
D.5  Introduced error plan evaluation
The modified plans were radiated on the treatment machine. This allowed a comparison of 
the measured error-introduced dose distributions with the calculated error-free dose distribu-
tion. Finally, the relative Anatomy- and Conventional-GAI change to the error-free GAIs was 
calculated.
 
III. rESuLtS 
A.  Open fields in the homogeneous phantom
The dose deviation of the anatomy dose at the isocenter compared to the measurements with 
the PC was on average over the four fields and four energies 1.1% ± 0.6%. The TPS isocenter 
dose compared with the PC measurement showed a mean deviation of 0.6% ± 0.4% and the 
anatomy versus the TPS isocenter dose showed a mean deviation of 0.7% ± 0.5%. Table 1 
summarizes the dose deviations for the different field sizes.
B.  VMAT fields in the homogeneous phantoms
All measured VMAT plans had a Conventional GAI of 100% for the passing criteria of 3 mm/3%. 
The GAI dropped to a mean value of 88.1% ± 7.3% for 1m/1%.
The mean value of the OCTAVIUS TPS Phantom GAI (3 mm/3%) for the four energies 
was 98.6%. The OCTAVIUS Anatomy Phantom GAI gave an average of 95.4% (3 mm/3%). 
For the water phantom, the average TPS Phantom GAI (3 mm/3%) was 100.0%. The Anatomy 
Phantom GAI (3 mm/3%) had an average of 98.5%. Concerning all energies and both phan-
toms, the mean Anatomy Phantom GAI (3 mm/3%) was 96.9% ± 0.4%. The average of the 
TPS Phantom GAI (3 mm/3%) was 99.3% ± 0.8%, and the Anatomy GAI (3 mm/3%) showed 
Table 1. Comparison of the mean dose measured in the isocenter using a pinpoint chamber with the dose calculated 
by the Anatomy option and by the Eclipse treatment planning system (TPS).
  2×2 cm2 5×5 cm2 10×10 cm2 20×20 cm2
 Anatomy vs. Pinpoint Chamber  1.5%±0.5%  1.3%±0.2%  0.9%±0.9%  0.7%±0.2%
 TPS vs. Pinpoint Chamber  0.9%±0.5%  0.8%±0.4%  0.4%±0.3%  0.3%±0.2%
 Anatomy vs. TPS  0.6%±0.4% 0.6%±0.4% 1.0%±0.7% 0.7%±0.4%
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an average of 97.7% ± 1.5%. The Anatomy GAI had the biggest standard deviation out of the 
four comparisons. In Fig. 3, the GAIs (3 mm/3%) with the standard deviation for the four dif-
ferent comparisons are shown, and in Fig. 4 the GAIs for the different DTA and DD constraints 
are presented. According to our internal guidelines for patient specific VMAT QA, plans are 
accepted if the QA GAI is above 95% (3 mm/3%).
c.  VMAt patient plan evaluation
All plans of the prostate cancer patients used to investigate the conversion algorithm passed 
the conventional ScandiDos QA test with 99.8% ± 0.4% Conventional GAI (3%/3 mm). The 
plans of the intracranial lesion passed with a mean GAI of 99.7% ± 0.4%.
For DTA = 3 mm and DD = 3%, the Anatomy GAI was 86.0% ± 5.0% (prostate) and 95.3% ± 
2.1% (intracranial lesions). The GAI for the PTV was 83.7% ± 8.8% and 90.6% ± 2.3% for 
prostate and intracranial lesions, respectively. For DTA = 3 mm and DD = 5%, the PTV-GAI 
were between 93.1% and 99.6%, and the Anatomy GAI between 90.1% and 99.2%. All results 
are shown in Table 2.
Fig. 3. GAI (3 mm/3%) for the four comparisons as a mean value for both phantoms and the four energies used. Error 
bars are the standard deviation.
Fig. 4. GAI for the four comparisons, as an average of both phantoms and the four energies. The red x = the Conventional-
GAI, the black circles = the TPS Phantom GAI, the green stars = the Anatomy Phantom GAI, and the pink crosses = the 
Anatomy GAI for the different DTA and DD. From the center to the right, the big red line is a relaxation of the DD and 
to the left, the red line is an relaxation of the DTA. Error bars are the standard deviation.
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d.  Introduced errors
Figure 5 shows the changes in the GAI index if a gantry positional error is introduced. For DTA = 
3 mm and DD = 3% and an angle error of 2°, the relative GAI change for Conventional GAI 
was -0.1% ± 0.1% considering all energies and both phantoms. The mean change in Anatomy 
GAI was 0.0% ± 0.5%. For a 10° angle error, the change in the Conventional GAI was -4.3% ± 
2.0% and in the Anatomy GAI the change was -5.8% ± 1.6%. 
In the case of an angle error of 2°, the mean Conventional GAI change over all energies 
and both phantoms with DTA = 1 mm and DD = 1% was -5.4% ± 1.2%. The mean change for 
the Anatomy GAI was -0.8% ± 1.7%. For an error of 10°, the Conventional GAI change was 
-25.2% ± 3.6% and for the Anatomy GAI, -19.9% ± 2.9%. 
IV. dIScuSSIon
Recently, 3D anatomy-based QA systems have gained popularity.(6-8,15-17) A more precise idea of 
the dose distribution within the patient becomes increasingly important with more sophisticated 
treatment plans. Anatomy-based QA allows access to structure specific GAI and DVHs (Fig. 1). 
This induces discussions about the clinical relevance of deviations between the measured and 
the TPS-calculated dose distribution within the patient. Radiation plan adjustments can then 
be made before the treatments start. 
In this study, the Delta4DVH Anatomy 3D QA system was evaluated. With two homoge-
neous phantoms the conversion algorithm was confirmed. Angular errors with a gravitational 
response up to 10° were introduced to investigate the relative change in the Anatomy GAI 
and the Conventional GAI. It was shown that the Delta4DVH Anatomy 3D QA detects the 
error as good as the conventional method. Furthermore, Delta4DVH Anatomy conversions for 
Table 2. Mean three-dimensional gamma agreement index (GAI) and standard deviation inside the PTV and the body 
of the patient using Delat4 Anatomy option. Mean GAI in the horizontal isocenter slice and mean dose deviation in the 
isocenter and mean GAI in the phantom (Conventional GAI).
  Prostate Brain
 Body GAI (3 mm/5%)  94.0%±2.9% 97.9%±1.5%
 PTV GAI (3 mm/5%)  97.3%±2.0%  94.4%±1.7%
 Body GAI (3 mm/3%)  86.0%±5.0% 95.3%±2.1%
 PTV GAI (3 mm/3%)  83.7%±8.8% 90.6%±2.3%
 Horizontal slice (3 mm/3%) 87.2%±5.1% 95.2%±2.3%
 Dose deviation (%)   2.4%±2.5%   1.3%±2.1%
 Conventional GAI (3 mm/3%)  99.8%±0.4% 99.7%±0.4%
Fig. 5. The relative GAI (3 mm/3%) change for a 2° and 10° gantry angle error. Error bars are the standard deviation.
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20 patients resulted in a PTV-GAI (3 mm/5%) of 97%. However, it dropped to 84% for the 
passing  criteria 3 mm/3%. All patient plans passed the conventional QA test (Conventional 
GAI > 95%, 3 mm/3%).
The anatomy dose conversion algorithm calculated the isocenter dose in a homogeneous 
phantom accurately for static open fields of 2 × 2 cm2 up to 20 × 20 cm2 and energies of X6, 
X10, X6FFF, and X10FFF. It was shown that the TPS predicts the isocenter dose slightly better 
than the back-projected Anatomy dose. 
The mean Anatomy Phantom GAI (3 mm/3%) showed that the anatomy dose (3D dose to 
patient) algorithm works for a homogeneous case. While all the Conventional GAI had 100.0%, 
the mean Anatomy GAI was 98%. Lowering the passing criteria to DTA = 1 mm and DD = 
1% resulted in a 28% lower GAI for the two comparisons with the back-projected Anatomy 
dose (Anatomy GAI and Anatomy Phantom GAI) than the two comparisons with the calcu-
lated TPS dose (TPS Phantom GAI and Conventional GAI) (Fig. 4). This may result from the 
different dose calculation algorithms used. Eclipse TPS uses the AAA algorithm, which is a 
more advanced algorithm than pencil beam that is used in the Delta4DVH Anatomy software.
(18) Another cause for the lower agreement may be that the diode grid resolution is too small to 
accurately determine the energy fluence used for dose calculation in the patient.
The error detection of the Delta4DVH Anatomy was as good as the conventional measurement. 
A gravitational gantry error up to 2° was not detectable, which was to be expected, as small 
random and systematic gantry position errors are relatively insignificant.(19) For the investigated 
two phantoms at a gantry error of 10°, six out of eight incorrect plans passed the conventional 
ScandiDos QA test (Conventional GAI > 95%, relative Conventional GAI change < 5%). 
With the Delta4DVH Anatomy, just two out of eight incorrect plans passed (Relative Anatomy 
GAI change < 5%). However, the problem is the large variation of the Anatomy GAI in the 
error-free case. One of the eight plans did not pass the Anatomy QA conditions (Anatomy 
GAI > 95%, 3 mm/3%), even with the error-free measurement, while all of them passed the 
standard ScandiDos QA test with 100% Conventional GAI. Therefore, it is difficult to judge 
the Anatomy QA results.
The constraints for the DD had to be loosened from 3% to 5% for real patient geometries. 
This is most likely due to inaccurate dose calculation using the pencil beam algorithm in the 
Delta4DVH Anatomy.(20) This is especially a problem for the prostate dose distributions, because 
the PTV includes parts of the air-filled rectal balloon. The average overall body GAI and PTV-
GAI rose by about 10% when changing the DD passing criteria from 3% to 5%.
A similar investigation was done for the MatriXXEvolution system, showing a dose deviation of 
the TPS of less than 3%, compared to the reconstructed dose in the patient.(15) The more accurate 
results for the MatriXXEvolution system compared to the Delta4DVH Anatomy can be explained 
by the different dose conversion algorithms. MatriXXEvolution uses a collapsed cone convolution 
algorithm,(21) which is in inhomogeneous media, superior to the pencil beam algorithm.
The 3DVH system was evaluated in a white paper by Sun Nuclear.(22) The authors created a 
plan and introduced errors into the plan. It was then irradiated on the conventional QA phantom 
and subsequently converted to dose in the patient. The conversion was done by perturbing the 
error-free dose distribution in the patient with the measured errors. The dose distributions with 
introduced errors from the planning system were compared with the ‘measured’ dose distribution 
in the patient. The plan error was quantified with the GAI (2 mm/2%) of the conventional QA 
(error-induced versus measured error-free plans). The perturbation algorithm converted even 
erroneous dose distributions, which had 12% conventional GAI, back to 96% anatomy GAI 
(error-free versus perturbation-corrected dose distributions). The authors reported dose devia-
tions in the range of -0.31% to 2.08%, which is similar to our results. However, the methods 
used are quite different and make a quantitative comparison difficult.
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V. concLuSIonS
The anatomy-based, patient-specific quality assurance system from ScandiDos (Delta4DVH 
Anatomy), evaluated with two phantoms, predicts the dose distribution correctly for a homo-
geneous case. The large variation of the GAI in the ‘error-free plans’ is a limiting factor when 
it comes to error detection. The constraints for the DD had to be loosened from 3% to 5% for 
real patient geometries, to achieve an acceptable GAI. The dose calculation algorithm is infe-
rior to that used in the TPS (Eclipse). This inaccuracy is assumed to be due to the pencil beam 
algorithm of the Delta4DVH Anatomy.
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